Fredun Pharmaceuticals Ltd

₹ 926 1.08%

25 Jul - close price

About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products^[1]

Key Points

Business Overview:^[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.

Website BSE

Market Cap ₹ 437 Cr.
Current Price ₹ 926
High / Low ₹ 984 / 635
Stock P/E 21.0
Book Value ₹ 299
Dividend Yield 0.08 %
ROCE 18.9 %
ROE 15.8 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 61.4% CAGR over last 5 years
Company's median sales growth is 26.8% of last 10 years

Cons

Debtor days have increased from 85.2 to 142 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	71.85	48.42	70.32	77.96	79.81	62.05	81.98	87.00	118.03	78.82	107.35	102.70	167.41
	66.46	44.55	63.52	70.66	67.55	54.44	72.37	76.48	106.87	68.34	93.40	89.48	149.97
Operating Profit	5.39	3.87	6.80	7.30	12.26	7.61	9.61	10.52	11.16	10.48	13.95	13.22	17.44
OPM %	7.50%	7.99%	9.67%	9.36%	15.36%	12.26%	11.72%	12.09%	9.46%	13.30%	12.99%	12.87%	10.42%
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	1.72	1.91	1.86	1.95	3.55	2.61	2.90	3.77	4.37	3.91	5.31	5.00	8.15
Depreciation	0.58	0.65	0.72	0.74	0.70	0.92	0.94	0.99	0.96	1.05	1.06	1.09	1.25
Profit before tax	3.09	1.31	4.22	4.61	8.01	4.08	5.77	5.76	5.83	5.52	7.58	7.13	8.04
Tax %	25.57%	27.48%	25.12%	25.16%	51.44%	41.18%	31.72%	26.74%	13.38%	25.18%	43.54%	25.25%	12.06%
	2.30	0.94	3.15	3.46	3.89	2.40	3.94	4.22	5.06	4.13	4.27	5.33	7.07
EPS in Rs	5.19	2.11	7.07	7.66	8.58	5.24	8.41	8.98	10.76	8.75	9.04	11.29	14.97
Raw PDF

Upcoming result date: 30 July 2025

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	21	25	42	57	60	97	113	134	222	275	348	456
	20	24	38	53	54	87	104	126	208	247	310	401
Operating Profit	1	2	4	3	6	10	8	8	14	28	38	55
OPM %	7%	7%	9%	6%	10%	11%	7%	6%	6%	10%	11%	12%
	0	0	1	2	0	0	1	1	2	2	1	0
Interest	1	1	2	2	2	3	4	4	5	9	14	22
Depreciation	1	1	1	1	1	1	2	2	2	3	4	4
Profit before tax	0	1	2	2	3	6	2	3	9	18	21	28
Tax %	47%	52%	42%	36%	34%	28%	24%	37%	26%	38%	27%	26%
	0	0	1	1	2	4	2	2	6	11	16	21
EPS in Rs	1.02	1.11	4.55	6.08	5.11	11.18	4.76	5.04	14.30	23.85	33.22	44.07
Dividend Payout %	0%	0%	13%	10%	12%	6%	14%	14%	5%	3%	2%	2%

Compounded Sales Growth
10 Years:	34%
5 Years:	32%
3 Years:	27%
TTM:	31%

Compounded Profit Growth
10 Years:	54%
5 Years:	61%
3 Years:	49%
TTM:	33%

Stock Price CAGR
10 Years:	%
5 Years:	31%
3 Years:	-3%
1 Year:	8%

Return on Equity
10 Years:	13%
5 Years:	13%
3 Years:	15%
Last Year:	16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	2	2	2	2	3	4	4	4	4	5	5	5
Reserves	0	0	1	2	19	35	37	39	64	92	117	137
	7	9	16	21	10	19	35	40	53	87	106	166
	8	11	24	30	47	47	65	79	66	74	81	179
Total Liabilities	18	23	43	56	79	105	141	162	187	257	308	487
	7	8	15	16	16	31	31	30	32	39	47	53
CWIP	0	1	0	4	11	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	0	1	2
	11	14	29	36	52	74	110	131	155	218	260	433
Total Assets	18	23	43	56	79	105	141	162	187	257	308	487

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-1	2	3	4	17	1	-11	0	-2	-14	-0	-29
	-2	-3	-6	-7	-8	-5	-1	-1	-4	-9	-8	-6
	2	1	3	3	-8	4	14	-1	7	25	6	38
Net Cash Flow	-0	0	1	-1	1	0	2	-2	1	1	-2	3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	59	75	98	131	94	67	126	112	148	46	68	142
Inventory Days	107	102	140	68	170	249	227	242	96	264	246	265
Days Payable	152	167	221	224	360	205	208	215	101	104	88	160
Cash Conversion Cycle	14	11	17	-24	-96	110	145	139	144	205	225	247
Working Capital Days	31	20	16	10	42	99	141	144	144	191	190	202
ROCE %	14%	14%	25%	18%	16%	21%	10%	10%	13%	18%	17%	19%

Shareholding Pattern

Numbers in percentages

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
	51.04%	50.34%	50.15%	49.62%	49.31%	49.16%	49.17%	49.17%	48.93%	48.93%	48.93%	48.93%
	1.68%	1.66%	1.65%	1.64%	1.60%	1.60%	1.60%	1.60%	1.59%	1.59%	1.59%	1.59%
	47.27%	48.00%	48.20%	48.74%	49.08%	49.24%	49.24%	49.23%	49.47%	49.47%	49.47%	49.49%
No. of Shareholders	3,901	4,138	4,521	4,625	6,313	6,837	7,507	7,511	8,018	8,121	7,976	7,906

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Jun 2025
	74.44%	54.04%	52.04%	52.04%	52.04%	51.27%	50.15%	49.17%	48.93%	48.93%
	0.00%	0.00%	1.68%	1.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	3.19%	2.19%	1.88%	1.88%	1.88%	1.69%	1.65%	1.60%	1.59%	1.59%
	22.37%	43.77%	44.40%	44.85%	46.08%	47.04%	48.20%	49.24%	49.47%	49.49%
No. of Shareholders	509	562	1,046	1,478	1,992	3,620	4,521	7,507	7,976	7,906

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls